Page 6 - Drug Makers In India

Bharat Bio looks for partners to manufacture, distribute iNCOVACC globally

Its local production ramp-up remains unhurried as demand for boosters reduces

Drug regulator halts production at Maiden Pharma's Sonipat unit

Centre forms panel to analyse causal relation between deaths and cough syrups

Pharma industry says taking steps to check misuse of codeine drugs

Sales declining anyway and there is no need to ban because of alleged misuse, say experts

Land parcels of pharma PSUs find no takers, but momentum likely in few mths

In December 2019 the decision was revised to allow sale of land to private entities as well through a competitive bidding process

Core brands, new launches to help Abbott India stock outperform: Analysts

Analysts expect double-digit growth for pharma major even if Q1 disappointed

Largest Ibuprofen API maker eyes double revenue in next four years

As part of de-risking their business, they have started reducing the share of ibuprofen in their overall turnover, and add more popular products to the portfolio

Streamlining trade margins on drugs priced Rs 100 and above likely

Drugs for ailments like chronic kidney disease, some high end antibiotics, anti-virals (anti-infectives), as well as some cancer drugs are likely to be brought under trade margin rationalization first

Ethical Code to keep doctor, drugmaker nexus at bay not mandatory yet

The recent controversy following income tax raids on Micro Labs, makers of popular paracetamol brand Dolo, is likely to make things move in making the UCPMP

Bharat Biotech says Phase 3 trial over, intranasal vaccine 'safe'

The Hyderabad-based company claimed that BBV154 is proven to be safe, well-tolerated and immunogenic in the subjects under controlled clinical trials

Glaxosmithkline Pharma Q1 consolidated net profit up 8% at Rs 116 crore

Drug manufacturers GlaxoSmithKline on Monday said its consolidated net profit increased to Rs 116 crore in the first quarter. Shares of the company closed at Rs 1,726.20 on BSE, said reports

Natl Pharma Pricing Authority fixes retail prices of 84 drug formulations

Drug pricing regulator NPPA has fixed the retail prices for 84 drug formulations, including those used for treatment of diabetes, headache and high blood pressure. The National Pharmaceutical Pricing Authority (NPPA) has also fixed the prices of formulations indicated to reduce increased cholesterol and triglycerides levels, among others. In exercise of the powers conferred by the Drugs (Prices Control) Order, 2013, the NPPA has fixed the retail prices of the medications, the regulator said in a notification. As per the order, a single tablet of Voglibose and (SR) Metformin Hydrochloride will cost Rs 10.47, excluding GST. Similarly, the price of Paracetamol and Caffeine has been fixed at Rs 2.88 per tablet. Besides, the price of one Rosuvastatin Aspirin and Clopidogrel capsule has been fixed at Rs 13.91. In a separate notification, NPPA said it has extended the revised ceiling price of liquid medical oxygen and oxygen inhalation (medicinal gas) till September 30 this year. The NP

Top 300 drug brands to have QR codes on label for ensuring authenticity

The Union Ministry of Health has made amendments to the Drugs Rules, 1945, to implement this

Price is the key growth driver of Indian pharma market, shows AWACS data

Market set to grow by 2.5-5% in calendar 2022. could even hit 5% due to a strong seasonal sales such as anti-infectives, and impact of NLEM drugs price hike

Sun Pharma plans to expand field force in India by 10% this fiscal

The Mumbai-based drug major currently employs around 11,000 Medical Representatives and related staff in India

Sun Pharma to launch new oral lipid lowering drug under Brillo brand

Claims drug has a new mechanism of action compared to currently available lipid lowering agents, is indicated for people with inherited genetic disorder

Mandaviya urges bulk drug manufacturers to invest more in research

The chemicals and fertilizers minister, who also holds the health portfolio, praised the industry players for playing a pivotal role during Covid times, not only domestically but also globally

India-made stimulants, Covid drugs dominate illegal imports in Switzerland

Around 150 of the packages seized were connected with the Coronavirus including anti-parasitics containing ivermectin, medicinal products containing hydroxychloroquine or antibiotics from India

Zydus Cadila gets USFDA tentative nod for epilepsy treatment drug

Zydus Cadila on Monday said it has received tentative approval from the US health regulator to market epilepsy treatment drug Brivaracetam tablets.

Govt engaging with drug makers to ramp up production of anti-fungal drug

The government is engaging with the drug manufacturers to ramp up the production of an antifungal drug used for the treatment of mucormycosis, says Chemicals and Fertilizers Ministry

Cipla inks pact with Eli Lilly to produce, sell Covid-19 treatment drug

Drug major Cipla on Monday said it has inked a pact with US-based Eli Lilly and Company to manufacture and produce baricitinib in the country for the treatment of Covid-19